Table 3.
5-year and 10-year overall survival (OS) of patients diagnosed between 2004 and 2016.
| Variable | 5-year OS | 10-year OS | ||
|---|---|---|---|---|
| Probability | 95% CI | Probability | 95% CI | |
| By stage | ||||
| 0 | 94% | 94-94% | 83% | 83-84% |
| I | 90% | 90-90% | 75% | 75-76% |
| II | 83% | 83-83% | 67% | 67-67% |
| III | 66% | 66-66% | 47% | 47-47% |
| IV | 23% | 23-23% | 9.20% | 8.9-9.5% |
| By molecular subtype∗ | ||||
| HR+, HER2- | 84% | 84-84% | — | — |
| HR+, HER2+ | 83% | 83-84% | — | — |
| HR-, HER2- | 71% | 71-71% | — | — |
| HR+, HER2+ | 77% | 76-77% | — | — |
| By histologic subtype | ||||
| Ductal carcinoma | 84% | 84-84% | 70% | 70-70% |
| Lobular carcinoma | 84% | 84-85% | 68% | 68-69% |
| Adenocarcinoma of mixed subtypes | 81% | 79-84% | 65% | 61-69% |
| Metaplastic carcinoma | 63% | 62-64% | 50% | 48-51% |
| Rare breast carcinomas | 92% | 91-92% | 80% | 79-81% |
| Inflammatory invasive carcinoma | 39% | 38-40% | 25% | 24-26% |
| Other carcinomas | 84% | 84-84% | 71% | 70-71% |
| Epithelial-myoepithelial | 56% | 55-57% | 44% | 43-45% |
| Intraductal papillary | 90% | 89-90% | 78% | 77-79% |
| Papillary | 83% | 82-84% | 63% | 62-65% |
| Fibroepithelial | 83% | 82-85% | 74% | 71-76% |
| Mesenchymal | 47% | 44-50% | 35% | 31-38% |
| Tumors of the nipple | 81% | 79-83% | 65% | 61-68% |
| Carcinoid tumor | 60% | 39-92% | 40% | 16-99% |
| Malignant lymphoma∗∗ | 65% | 41-100% | — | — |
| By race | ||||
| White | 84% | 84-84% | 69% | 69-70% |
| Black | 78% | 78-78% | 63% | 63-63% |
| Other, including Asian and Pacific Islander | 90% | 90-90% | 81% | 80-81% |
| By facility type | ||||
| Community cancer program | 80% | 80-80% | 63% | 63-64% |
| Comprehensive community cancer program | 83% | 83-83% | 68% | 68-68% |
| Academic cancer program | 85% | 85-85% | 72% | 72-72% |
| Integrated cancer program | 84% | 84-84% | 69% | 69-70% |
∗10-year OS data is not available by receptor subtype, as HER2 status is not documented in NCDB prior to 2009. ∗∗10-year OS data also not available for patients with malignant lymphoma of the breast due to the year of diagnosis within the last years.